Arcadia Investment Management Corp MI Sells 8,477 Shares of Becton, Dickinson and Company (NYSE:BDX)

Arcadia Investment Management Corp MI lowered its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 22.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,011 shares of the medical instruments supplier's stock after selling 8,477 shares during the period. Becton, Dickinson and Company accounts for about 1.2% of Arcadia Investment Management Corp MI's investment portfolio, making the stock its 27th largest position. Arcadia Investment Management Corp MI's holdings in Becton, Dickinson and Company were worth $6,645,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Becton, Dickinson and Company by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock worth $6,067,196,000 after purchasing an additional 184,288 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in Becton, Dickinson and Company by 36.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock worth $2,751,187,000 after purchasing an additional 3,219,317 shares during the last quarter. Geode Capital Management LLC increased its position in Becton, Dickinson and Company by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock worth $1,437,161,000 after purchasing an additional 66,024 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 15.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock worth $1,401,126,000 after purchasing an additional 810,345 shares during the last quarter. Finally, First Eagle Investment Management LLC increased its position in Becton, Dickinson and Company by 31.4% in the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock worth $1,004,132,000 after purchasing an additional 1,057,879 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In other news, EVP David Shan sold 1,166 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the sale, the executive vice president owned 4,575 shares in the company, valued at approximately $783,194.25. The trade was a 20.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Up 1.3%

Becton, Dickinson and Company stock traded up $2.30 during trading hours on Thursday, hitting $177.80. The company had a trading volume of 1,015,042 shares, compared to its average volume of 2,068,726. The firm has a market cap of $50.96 billion, a P/E ratio of 33.90, a P/E/G ratio of 1.32 and a beta of 0.25. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a 50-day moving average price of $172.03 and a two-hundred day moving average price of $206.75.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. The company had revenue of $5.27 billion during the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the company earned $3.17 EPS. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were issued a $1.04 dividend. The ex-dividend date was Monday, June 9th. This represents a $4.16 annualized dividend and a dividend yield of 2.34%. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.

Analyst Upgrades and Downgrades

Several research analysts have commented on BDX shares. Stifel Nicolaus dropped their price objective on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective for the company. in a research note on Friday, May 2nd. Wells Fargo & Company lowered shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their price objective for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Finally, Morgan Stanley dropped their price objective on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of "Hold" and a consensus target price of $219.22.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.